Mynx Control
Payments companies reported to CMS as associated with Mynx Control. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Mynx Control, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Mynx Control
These are the largest totals companies reported as associated with Mynx Control. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Joseph Bumgarner | Raleigh, NC | Clinical Cardiac Electrophysiology | $10,927.41 |
| Joseph Degregorio | Glen Ridge, NJ | Cardiovascular Disease | $7,775.03 |
| Sanjaya Gupta | Kansas City, MO | Clinical Cardiac Electrophysiology | $6,905.45 |
| Litsa Lambrakos | Miami, FL | Clinical Cardiac Electrophysiology | $6,900.00 |
| Thomas Davis | St Clair Shores, MI | Cardiovascular Disease | $6,668.76 |
| Ron Waksman | Washington, DC | Interventional Cardiology | $5,250.00 |
| Sahil Parikh | New York, NY | Interventional Cardiology | $1,852.06 |
| Mohammad Ansari | Lubbock, TX | Interventional Cardiology | $1,649.14 |
| Vladimir Lakhter | Philadelphia, PA | Cardiovascular Disease | $1,041.67 |
| Manish Parikh | Brooklyn, NY | Internal Medicine | $977.06 |
Prescribed Mynx Control?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.